Bifido비피도
238200 · KOSDAQ · ₩238200 · 비피도
- Market cap
- ₩20B
- Enterprise value
- ₩22B
- P/E
- 10.6×
- P/B
- 0.4×
- Dividend yield
- 0.0%
- ROE
- 3.8%
- Net margin
- 12.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−40.3% from the high
₩2,045Today: ₩2,350 – ₩2,500₩3,995
Returns
- 1W−5.9%
- 1M−9.5%
- 3M−2.7%
- 6M−15.7%
- YTD−22.2%
- 1Y−36.6%
- Volume today
- 925
- 0.3× the 20-day average
- Traded today
- ₩2.2M
- Listed shares
- 8,180,000
- EPS (12 months)
- ₩226
- Earnings yield 9.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 30 of 100 (50 is a normal day for this stock).
- MomentumWeak-9.1% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Bifido stock overview
Bifido (비피도, KRX: 238200) is listed on KOSDAQ, in the Food & Beverage sector. The company develops and manufactures probiotic raw materials and finished health functional foods, built around proprietary Bifidobacterium strains discovered from Korean infants, and sells its own brand BIFIDO LAB along with contract development and manufacturing (ODM) services for domestic and overseas clients. Its shares closed at ₩2,385 on Oct 27, 2026, down 0.21% on the day, giving it a market value of ₩20B.
Key facts
- Market cap
- ₩20B
- Sector
- Food & Beverage
- Latest price change
- −0.21%
- As of
- Oct 27, 2026
- Main business
- The company develops and manufactures probiotic raw materials and finished health functional foods, built around proprietary Bifidobacterium strains discovered from Korean infants, and sells its own brand BIFIDO LAB along with contract development and manufacturing (ODM) services for domestic and overseas clients.
Quick answers about Bifido
- What does Bifido do?
- The company develops and manufactures probiotic raw materials and finished health functional foods, built around proprietary Bifidobacterium strains discovered from Korean infants, and sells its own brand BIFIDO LAB along with contract development and manufacturing (ODM) services for domestic and overseas clients. It also develops microbiome-based therapies, including an engineered live biotherapeutic platform called BiGex, with its rheumatoid arthritis candidate withdrawn in late 2025.
- What is the market cap of Bifido?
- The market capitalisation of Bifido was ₩20B at the close on Oct 27, 2026.
- When is the next earnings report from Bifido?
- Korean companies rarely announce results dates in advance. Based on when Bifido filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company develops and manufactures probiotic raw materials and finished health functional foods, built around proprietary Bifidobacterium strains discovered from Korean infants, and sells its own brand BIFIDO LAB along with contract development and manufacturing (ODM) services for domestic and overseas clients. It also develops microbiome-based therapies, including an engineered live biotherapeutic platform called BiGex, with its rheumatoid arthritis candidate withdrawn in late 2025.
Written by AI from the company's latest annual report.
- Korean name
- 비피도
- Sector
- Food & Beverage
- Themes
- K-food & ramen
- CEO
- 이원범, 박명수(각자대표)
- Founded
- Oct 1999
- Listed
- Dec 2018
- Listed shares
- 8,180,000
- Fiscal year ends
- Month 12
- Website
- bifido.com
Similar companies
- Samyang Foods003230 · ₩8.5T₩1,133,000+1.52%
- Orion271560 · ₩4.4T₩111,500−1.33%
- CJ Cheiljedang097950 · ₩2.5T₩168,700−0.71%
- Nongshim004370 · ₩2.4T₩393,0000.00%
- Otoki007310 · ₩1.2T₩307,500−0.97%
- Hite Jinro000080 · ₩1.1T₩15,660−1.20%
- Lotte Wellfood280360 · ₩1.1T₩118,500−0.08%
- Lotte Chilsung Beverage005300 · ₩881B₩95,000+1.39%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Merger Completion Report (Asset Acquisition and Transfer)Aug 14, 2026
- Amended: Quarterly report (Mar 2026)Jul 24, 2026
- [Amended Filing] Major Matters Report (Decision on Disposal of Tangible Assets)May 19, 2026
- Quarterly report (Mar 2026)May 15, 2026
Titles in Korean until English translations are added.
Also known as: Bifido / 비피도 / 238200 / KRX:238200
Source: KRX statistical information